AbbVie announces positive top-line results from second Phase III study investigating Elagolix in patients with endometriosis

AbbVie, in co-operation with Neurocrine Biosciences, has announced positive top-line results from the second of two replicate pivotal Phase III clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer pain from endometriosis. Trial results show that after 6 months of continuous treatment, both doses of Elagolix (150 mg once daily and 200 mg twice daily) met the study's co-primary endpoints. Elagolix reduced scores of menstrual pain (dysmenorrhea, DYS) and non-menstrual pelvic pain (NMPP) associated with endometriosis, at month three and month six, as measured by the Daily Assessment of Endometriosis Pain scale. Responder rates for the co-primary endpoints from this second Phase III pivotal study are consistent with results from the first Phase III pivotal study.